Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response

Open access
Tintle, Suzanne, Shemer, Avner, Suárez-Fariñas, Mayte, Fujita, Hideki, Gilleaudeau, Patricia, Sullivan-Whalen, Mary, Johnson-Huang, Leanne, Chiricozzi, Andrea, Cardinale, Irma, Duan, Shenghui, Bowcock, Anne, Krueger, James G., Guttman-Yassky, Emma·2011·Journal of Allergy and Clinical Immunology

Abstract

Background Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly Th2/“T22” immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate-to-severe AD. In psoriasis, NB-UVB has been found to suppress the Th1/Th17-polarization with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in AD. Objective To evaluate the effects of NB-UVB on immune and barrier abnormalities in AD, aiming to establish reversibility of disease and biomarkers of therapeutic response. Methods 12 moderate-to-severe chronic AD patients received NB-UVB phototherapy 3 times weekly for up to 12 weeks. Lesional and non-lesional skin biopsies were obtained before and after treatment and evaluated by gene-expression and immunohistochemistry studies. Results All patients had at least a 50% reduction in SCORing of AD (SCORAD) index with NB-UVB phototherapy. The Th2, “T22,” and Th1 immune pathways were suppressed and measures of epidermal hyperplasia and differentiation normalized. The reversal of disease activity was associated with elimination of inflammatory leukocytes, Th2/“T22”- associated cytokines and chemokines, and normalized expression of barrier proteins. Conclusions Our study shows that resolution of clinical disease in patients with chronic AD is accompanied by reversal of both the epidermal defects and the underlying immune activation. We have defined a set of biomarkers of disease response that associate resolved Th2 and “T22” inflammation in chronic AD patients with reversal of barrier pathology. By showing reversal of the AD epidermal phenotype with a broad immune-targeted therapy, our data argues against a fixed genetic phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2011.05.042

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 220

Metadata

Authors
Tintle, S., Shemer, A., Suárez-Fariñas, M., Fujita, H., Gilleaudeau, P., Sullivan-Whalen, M., Johnson-Huang, L., Chiricozzi, A., Cardinale, I., Duan, S., Bowcock, A., Krueger, J. G., & Guttman-Yassky, E.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2011-09
Volume
128
Issue
3
Pages
583-593.e4
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2163968757
Cited by
220
References
11
FWCI
12.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. https://app.cochat.ai/papers/10.1016/j.jaci.2011.05.042
The paper
Tintle, S., Shemer, A., Suárez-Fariñas, M., Fujita, H., Gilleaudeau, P., Sullivan-Whalen, M., Johnson-Huang, L., Chiricozzi, A., Cardinale, I., Duan, S., Bowcock, A., Krueger, J. G., & Guttman-Yassky, E. (2011). Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2011.05.042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.